Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human albumin animal models for drug evaluation, Toxicology and immunogenicity studies

a human albumin and animal model technology, applied in the field of human albumin animal model for drug evaluation, toxicology and immunogenicity studies, can solve the problem of extremely disappointing results when used in human trials

Inactive Publication Date: 2006-02-02
CARTER DANIEL C
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides animal models that contain or express human serum albumin, which is the main protein in human blood. These models are more effective in accurately assessing how drugs or other chemicals will react in humans than traditional animal models. The invention also provides methods for preparing and using these animal models in evaluating drugs, vaccines, chemicals, and other materials used on humans. The animal models can help to better understand the safety and efficacy of new drugs, vaccines, or other medicines. Additionally, the invention provides animal models that reflect genetic diseases and disease states, which can be useful in evaluating drugs or vaccines for treating or preventing such diseases. Overall, the invention provides a more accurate and reliable way to assess the safety and efficacy of drugs and other materials used on humans."

Problems solved by technology

As a result, the literature is replete with examples of drugs which appeared to be extremely effective in animal testing only to show extremely disappointing results when used in human trials.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human albumin animal models for drug evaluation, Toxicology and immunogenicity studies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Injection of Albumin into NAR Rats

[0035] In accordance with the present invention, a natural mutant rat which does not express or contain its own serum albumin, namely an NAR rat identified as ODNAR10, was utilized as an animal model in accordance with the present invention by injecting the animal with suitable amounts of human serum albumin. In this example, the NAR was given intravenous albumin injection / infusions by initially injecting relatively small amounts of HSA solution into the animal (1 mL). The amount of blood administered to this initial NAR rat was monitored over a 25 day period and this monitoring showed that a significant amount of human albumin had accumulated in the rat's system during this time, as shown by the chromatograph of FIG. 1, wherein column 10 represents the blood sample obtained from ODNAR10. By the end of the treatment (when the animal expired during anesthesia), ODNAR10 had received a total of 2.125 g HSA administered over a 25 day period (Table I)....

example 2

Transgenic NAR Rats

[0039] In accordance with the present invention, transgenic animal models were prepared which were transfected with the gene for human serum albumin. In this example, first generation NAR rat pups were sent to TOSK for injection of the HSA gene within their proprietary STEALTHGENE vector. Pups were sent to TOSK between the weights of 80 and 120 g, as per their instructions, due to their procedure being most amenable to this age and weight of rat. From the breeding program we have instigated for NAR rats, we have learned that females need to be on the order of 230 g before they conceive reliably. As of today, our heaviest females returned from TOSK have been transfected with the gene for human serum albumin and are 185.5 g and 190 g and growing at a rate of about 15 g every 3 to 4 days. In accordance with the invention, these animals are thus suitable as models for animal testing, and because they have been genetically transformed, such animals will be useful in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
volumeaaaaaaaaaa
osmotic blood pressureaaaaaaaaaa
Login to View More

Abstract

An animal model is provided which is genetically engineered to express human serum albumin, and such animals may be advantageously used in assessing drugs, vaccines or other therapeutic compounds that may be used in humans. In addition, an animal model is provided which does not manufacture its own albumin and which has been injected with human serum albumin. Through the use of these animal models, drugs and other chemicals can be more accurately assessed in physiological environments that reflect the conditions to be expected in humans, and such models will be useful in assessing new drugs and evaluating toxic substances for potential dangers as carcinogens, mutagens, etc. Other applications include evaluating immunological properties of various albumin-engineered proteins which might be administered to humans as therapeutics or vaccines, and research of disease states, such as genetic diseases, to provide further insight in treating these diseases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional application of U.S. Ser. No. 10 / 171,688, filed Jun. 17, 2002. This application also claims the benefit of U.S. Provisional Application Ser. No. 60 / 298,124, filed Jun. 15, 2001, incorporated herein by reference.FIELD OF THE INVENTION [0002] This invention relates in general to an animal model with serum attributes which have similar or identical properties and pharmokinetics with the human blood system in order to improve the assessment and development of new therapeutics and vaccines and to provide more reliable systems for identifying chemicals or drugs that may be carcinogenic or toxigenic to humans, and more specifically relates to transgenic animals and other animal models which contain and / or express human serum albumin and which thus can be used in methods of drug evaluation, toxicology and immunogenicity so as to provide a far more accurate picture of how drugs and chemicals will react in humans t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027C07K14/765C12N15/85
CPCA01K67/0278A01K2207/15A01K2217/00C12N15/8509A01K2227/105A01K2267/03C07K14/765A01K2217/05A61P43/00
Inventor CARTER, DANIEL C.
Owner CARTER DANIEL C
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com